Sensei Biotherapeutics Inc (NAS:SNSE)
$ 0.6998 -0.0115 (-1.55%) Market Cap: 17.55 Mil Enterprise Value: -33.89 Mil PE Ratio: 0 PB Ratio: 0.31 GF Score: 41/100

Sensei Biotherapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 13, 2023 / 12:00PM GMT
Release Date Price: $1.31 (-9.66%)
John Celebi
Sensei Biotherapeutics, Inc. - President & CEO

Hello, everyone. Thank you for your time and attention today. I'm very happy to present to you Sensei Bio's conditionally active antibodies for immuno-oncology. But first, I just want to thank Oppenheimer for inviting us to the conference and for their continued support. Oppenheimer played an important role in Sensei Bio's IPO two years ago.

As you can see from our cover slide, we are an immuno-oncology company developing conditionally active antibodies. And we're going to talk about what conditionally active antibodies are throughout the presentation.

But before I get started, I will be making forward-looking statements here today, and this is our disclaimer.

Now, at Sensei Bio, we're particularly focused on one of the key challenges in immuno-oncology, and that is that many antibodies fail because of off-tumor binding. Systemically delivered immuno-oncology drugs are developed in a fairly canonical way and are developed to bind to targets both in the tumor and in the periphery. And this creates, in our view,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot